

Changes in liver function tests caused by COVID-19 and impact on patient outcome: a systematic review

Tiago Almeida-Costa,^{1*}  María Adriely Cunha-Lima,¹  Isadora Kniess,² Levi Marques-Vieira,² Leda María Delmondes-Freitas Trindade.³ 

OPEN ACCESS

Citation:

Almeida-Costa T, Cunha-Lima MA, Kniess I, Marques-Vieira L, Delmondes-Freitas LD. Changes in liver function tests caused by COVID-19 and impact on patient outcome: a systematic review. *Rev Colomb Gastroenterol.* 2021;36(3):302-312. <https://doi.org/10.22516/25007440.713>

¹ Undergraduate student of Medicine at Universidad Tiradentes (UNIT). Aracaju, SE, Brazil.

² Universidad del Rosario (UNR). Rosario, Argentina.

³ Degree in Health Science. Professor of the Medicine course, UNIT. Aracaju, SE, Brazil.

*Correspondence: Tiago Almeida Costa. tialmeidac@gmail.com

Received: 25/01/21

Accepted: 07/06/21



Abstract

Introduction: In March 2020, the World Health Organization declared COVID-19, a disease caused by SARS-CoV-2 infection, a global pandemic. This virus uses human angiotensin-converting enzyme 2 (ACE2) as its receptor for entry. ACE2 is found in pulmonary, cardiac, gastrointestinal, hepatic, renal and vascular tissues, thus posing a potential risk for multisystemic involvement. The excessive release of inflammatory cytokines in COVID-19, as well as the use of medicines with hepatotoxic potential for the treatment of its symptoms, can damage the liver. **Objective:** To analyze the relationship between changes in liver function tests caused by SARS-CoV-2 infection and their impact on patient prognosis. **Methodology:** This is a systematic review of studies selected from the PMC, LILACS and SciELO databases. After applying the inclusion and exclusion criteria, 30 articles were included in the final sample for analysis. **Results:** Elevated AST (aspartate aminotransferase) enzyme levels were reported most frequently and were found in 4 695 cases, while ALT (alanine aminotransferase) elevation was described in 3 226 cases. It was observed that patients with digestive symptoms were more likely to present hepatocellular damage and, consequently, enzymatic alterations. Furthermore, 28.9 % of individuals with impaired liver function died, compared to 9 % of patients with normal function. **Conclusion:** It is evident that there is a relationship between liver involvement in COVID-19 and mortality. However, there is still a limitation in the number and, more importantly, the homogeneity of the research that performed this assessment.

Keywords

Liver function tests; Mortality; Coronavirus infections.

INTRODUCTION

In December 2019, China publicly reported its first cases of coronavirus 2019 (COVID-19), a disease caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and in March 2020, due to the global spread of the virus, the World Health Organization (WHO) officially declared the COVID-19⁽¹⁾ pandemic.

SARS-CoV-2, the novel coronavirus, is characterized by being an enveloped single-chain ribonucleic acid (RNA) virus of the *Coronaviridae* family with an incubation period of around 14 days, and a median incubation period from 4 to 6 days^(2,3). Person-to-person transmission of COVID-19 occurs due to contact or handshaking as well as to contact with droplets of saliva produced by sneezing or coughing infected individuals which are emitted through air⁽³⁾.

The pathogenic mechanism of SARS-CoV-2 consists in using the angiotensin-converting enzyme II (ECA-II) as a receptor for its entry into the cell⁽²⁾. ACE-II is not only present in the pulmonary alveoli, but also in cardiac myocytes, gastrointestinal tract, liver, kidneys, vascular endothelial cells and muscle cells in arteries, reflecting the involvement of various organs and tissues, justifying the variety of symptoms of this disease⁽⁴⁾.

The clinical manifestation of COVID-19 is variable and may be asymptomatic, with mild to moderate symptoms, especially fever, headache, cough, nasal congestion and gastrointestinal symptoms; to severe manifestations, especially in a patient with an association of comorbidities and multisystem involvement^(5,6). The pathophysiology of COVID-19 has not been fully elucidated yet; however, one of its mechanisms is the exacerbated release of inflammatory cytokines that ends up in multisystem involvement, which can trigger vascular and coagulative changes⁽⁷⁾.

As for liver damage, due to the state of hyperinflammation by the “cytokine storm” and dysregulation of coagulation, there are laboratory analyzes of mild thrombocytopenia, prolongation of prothrombin time, elevation of ferritin and C-reactive protein (CRP)⁽⁷⁾. There are reports in the literature regarding liver damage associated with secondary sepsis to COVID-19^(8,9), as well as a description of the use of hepatotoxic drugs in the symptomatic therapeutic treatment of COVID-19 and its complications^(4,10).

In order to globally assess the physiology of the liver and identify liver lesions, biochemical markers are used: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and its fractions, alkaline phosphatase and γ -glutamyltransferase (GGT), which when above reference values indicate changes in liver function and possible hepatocellular damage⁽¹¹⁾.

Being still a very recent disease, COVID-19 lacks more studies to evaluate possible tissue damage, once the virus access to different organs has been reported. Given that the aim of this review is to correlate the development of alterations in liver function caused by SARS-CoV-2 and its impact on the clinical evolution of the patient with the infection, it is worth emphasizing that, so far, it is not clear whether the mechanism that causes liver damage in SARS-CoV-2 infection is the result of the disease and its pathophysiological mechanisms or the current treatment.

MATERIAL AND METHODS

This study consists of a systematic review that mainly aims to correlate the hepatic alterations caused by SARS-CoV-2 infection with patient prognosis with this infection. The databases of PubMed Central[®] (PMC), the Latin American

and Caribbean Health Sciences Literature (LILACS) and the Scientific Electronic Library Online (SciELO) were selected to investigate the topic related to this study. In addition, the following descriptors were defined to carry out the research aimed at the proposed topic: “injury” (D1), “hepatic” (D2), “coronavirus” (D3) and “COVID-19” (D4), in addition to the Boolean operator “Y”. In light of this, “D1” associations were used.

Then, the following filters were defined in order to be used in the searches: randomized trial, observational studies (cohort, cross sectional, and case-control), case series, articles published in the last year and full text, which were used as criteria to be included in the study. Also, as it is a recent topic, there was no language restriction. The exclusion criteria used were studies that did not address the topic or did not present sufficient data in order to achieve the objective of this review. Editorials, comments, meta-analyses and review articles were also excluded. It should be noted that, due to the fact that it is a recent disease, it was not possible to trace homogeneity in all the selected articles.

After applying the inclusion and exclusion criteria, 4742 articles were found in the databases, 4523 were excluded and only 219 articles were included. Subsequently, titles and abstracts were read in order to exclude studies that did not address the proposed topic; thus, 47 studies were chosen to be fully read. After reading, 17 articles that did not contain sufficient data to meet the objectives of this study were excluded; therefore, 30 articles were defined to make up the database of this systematic review (Figure 1).




Figure 1. PRISMA flow diagram of the study. Research data, 2020.

No articles were selected from the LILACS database, as only two articles were found during the search, which did not address the proposed topic. In SciELO, there were four articles in the research, of which only one had sufficient data to achieve the objective proposed in this study. It is worth noting that two reviewers independently carried out the entire article selection process.

In order to apply the kappa index to analyze the concordance index between reviewers, authors María Adrieli Cunha Lima (ML) and Tiago Costa (TC) did the article selection independently, and if the value determined, for instance, a lack of concordance, poor or moderate concordance, a third reviewer (Isadora Kniess [IK]) would be selected. Therefore, IK would choose an article at the point of intersection of the two previous reviewers with the purpose of eliminating the initial discrepancy (Table 1).

Table 1. Contingency Index

		Reviewer TC		
		Cat. 1- Yes	Cat. 2- No	Total
Reviewer ML	Cat. 1- Yes	28	13	41
	Cat. 2- No	17	4684	4701
	Total	45	4697	4742

Cat.: category. Source: Research data, 2020.

The kappa index was applied and a value of 0.648 was obtained, which, according to Landis and Koch⁽¹²⁾, is interpreted as a strong agreement, which is why the systematic review can take place (Table 2).

Table 2. Kappa Index

Indexes	Category 1*	Category 2**
Category kappa	0.648	0.648
Standard category kappa error	0.0641	0.0601
95% CI for category kappa	Sup.: 0. 5224 Inf.: 0. 7736	Sup.: 0. 5302 Inf.: 0. 7658

*Articles included in the study. **Articles excluded from the study. CI, Confidence Interval; Inf.: Inferior; Sup.: Superior. Source: Research data, 2020.

RESULTS

Table 3 shows that, in total, 19,234 cases of individuals infected with SARS-CoV-2 were analyzed, since 70% (n = 21) of the articles were written in China. In addition, it is

worth mentioning that only one journal (3.33%), of those that published the studies used in this systematic review, has an impact factor below 1.0.

Regarding the characteristics of the sample, there is a higher prevalence of men, 9943 cases (54.1%), than of women, 8431 cases (45.9%). In addition, only 12 (40%) articles mentioned there were hepatic comorbidities in a percentage of the sample, and only 2 (6.7%) had a percentage greater than 9% of the sample. It is worth noting that 3 (10%) articles sampled only patients admitted to the Intensive Care Unit (ICU), while 2 (6.7%) articles analyzed only cases of COVID-19 deaths (Table 4).

The increase in AST (4695 cases) prevailed in relation to the total number of cases, when compared to ALT (3226 cases) (Table 5). Only one study did not mention changes in aminotransferase levels⁽³⁹⁾.

Asghar MS et al.⁽¹³⁾ recorded, in a sample of 100 patients, two cases of fatal liver failure, in those who had previous hepatic enzyme changes. Jiang S et al.⁽²⁴⁾, in a sample of 131 COVID-19 patients, mentioned that 76 (58%) of them had liver damage, of which 81.5% corresponded to the most severe cases.

Three studies mentioned death due to severe liver injury. Jin A et al.⁽²⁵⁾, with 45 cases, mentioned that only one patient developed severe liver failure (Child-Pugh class C) and evolved to death; that of Zhang B et al.⁽³⁸⁾, in which out of the 64 patients with liver damage, only one evolved to death; and the study of Zhang S et al.⁽⁴⁰⁾ with a sample of 146 deaths, 15 (10.3%) of such cases died due to acute liver damage.

Pan L et al.⁽²⁹⁾, when evaluating digestive symptoms and changes in hepatic enzymes (ALT and AST), in a sample of 204 COVID-19 patients, observed that from a group of 49 patients with increased ALT and AST, 38 mentioned digestive symptoms. They concluded that those who had digestive symptoms were more likely to have hepatocellular damage and, consequently, enzymatic changes. Wang Y et al.⁽³⁵⁾ mentioned that the increased level of these enzymes was related not only to the severity of the disease, but also to a higher incidence of coughing.

Zhang G et al.⁽³⁹⁾ associated an increase in ALT and AST enzymes, and a reduction in the level of total proteins with an increased risk of ICU admission, mechanical ventilation, and death, in which near half of the patients had impaired liver function. This condition was also cited by Cai Q et al.⁽¹⁵⁾, when they identified 298 COVID-19 patients, of which 44 (14.8%) had liver damage, and was more common in those who showed a more severe clinical picture. However, they did not clarify how many of them were considered serious cases.

Chen LY et al.⁽¹⁷⁾ mentioned that, out of a sample of 502 individuals, 301 (60%) patients had abnormal liver function upon admission and this condition correlated

Table 3. Features of studies selected for review

Article	Journal	Type of study	Place of study	Sample (n)
Asghar MS et al. ⁽¹³⁾	Cureus IF: 1.90	Retrospective	Pakistan	100
Bahl A et al. ⁽¹⁴⁾	Internal and Emergency Medicine (IF: 2322)	Multicenter cohort	United States	1461
Cai Q et al. ⁽¹⁵⁾	Allergy (IF: 8706)	Retrospective	China	298
Chen J et al. ⁽¹⁶⁾	The Journal of Infection (IF: 4603)	Retrospective	Shanghai (China)	249
Chen LY et al. ⁽¹⁷⁾	Journal of Digestive Diseases (IF: 2937)	Retrospective	Wuhan (China)	502
Chen N et al. ⁽¹⁸⁾	Lancet (IF: 60 392)	Retrospective	Wuhan (China)	99
Davies P et al. ⁽¹⁹⁾	The Lancet Child & Adolescent Health (IF: 8543)	Multicenter observational	United Kingdom	78
Du RH et al. ⁽²⁰⁾	Annals of the American Thoracic Society (IF: 4836)	Multicenter observational	China	1017
Falasca L et al. ⁽²¹⁾	The Journal of Infectious Diseases (IF: 5186)	Description	Italy	22
Fan Z et al. ⁽²²⁾	Clinical gastroenterology and Hepatology (IF: 8549)	Single-center retrospective	Shanghai (China)	100
Hu W et al. ⁽²³⁾	Annals of Translational Medicine (IF: 3297)	Single-center retrospective	Wuhan (China)	16
Jiang S et al. ⁽²⁴⁾	Frontiers in Medicine (IF: 3.9)	Multicenter observational	Zhejiang (China)	131
Jin A et al. ⁽²⁵⁾	Biosafety and Health (IF: 1972)	Descriptive	Beijing (China)	45
Lei F et al. ⁽²⁶⁾	Journal of Hepatology AASLD (IF: 14 679)	Retrospective multicenter cohort	China	5771
Luo S et al. ⁽²⁷⁾	Clinical Gastroenterology and Hepatology (IF: 8549)	Retrospective	Wuhan (China)	183
Monterde VB et al. ⁽²⁸⁾	Biomedicines (IF: 4717)	Retrospective	Zaragoza (Spain)	540
Pan L et al. ⁽²⁹⁾	The American Journal of Gastroenterology (IF: 10 383)	Descriptive and multicenter	Hubei (China)	204
Ramachandran P et al. ⁽³⁰⁾	Journal of Clinical and Experimental Hepatology (IF: 1150)	Single-center retrospective	New York (United States)	145
Richardson S et al. ⁽³¹⁾	Journal of the American Medical Association (IF: 14 780)	Case series	New York (United States)	5700
Schattenberg JM et al. ⁽³²⁾	United European Gastroenterology Journal (IF: 3549)	Case series	Germany	44
Shi M et al. ⁽³³⁾	Journal of Clinical Laboratory Analysis (IF: 1.54)	Descriptive and multicenter	China	161
Teich VD et al. ⁽³⁴⁾	Einstein (IF: 0.261)	Unicentric retrospective	Brazil	510
Wang Y unicentric et al. ⁽³⁵⁾	Journal of Hepatology (IF: 20 582)	Retrospective	China	156
Xie H et al. ⁽³⁶⁾	Liver International (IF: 5175)	Retrospective	China	79
Yu Y et al. ⁽³⁷⁾	Critical Care (IF: 6700)	Multicenter observational	Wuhan (China)	226
Zhang B et al. ⁽³⁸⁾	PLoS One (IF: 2740)	Retrospective	China	82
Zhang G et al. ⁽³⁹⁾	Respiratory Research (IF: 3890)	Retrospective	China	95
Zhang S et al. ⁽⁴⁰⁾	Critical Care (IF: 6700)	Retrospective multicenter cohort	China	828
Zhou F et al. ⁽⁴¹⁾	Lancet (IF: 60 392)	Retrospective multicenter cohort	Wuhan (China)	191
Zhou J et al. ⁽⁴²⁾	Medicine (Baltimore) (IF: 2133)	Descriptive	Changsha (China)	201

IF: Impact Factor. Source: Research data, 2020.

Table 4. Features of studies selected for review

Article	Age range (years)	Sex (M/F)	Hepatic comorbidities	Admission to the ICU	Deaths
Bahl A et al. ⁽¹³⁾	Median: 62 (18 to > 80)	770/691	-	374 (25.6 %)	327 (22.4 %)
Zhou J et al. ⁽¹⁴⁾	Between 1 and 84	102/99	-	45 (22.4 %)	2 (0.99 %)
Jin A et al. ⁽¹⁵⁾	Average: 58.8 (between 7 and 94)	18/27	-	9 (20 %)	5 (11.1 %)
Asghar MS et al. ⁽¹⁶⁾	Average: 52.58	69/31	Chronic liver disease: 9 (9 %)	33 (33 %)	22 (22 %)
Monterde VB et al. ⁽¹⁷⁾	Average: 70 (between 22 and 99)	291/249	-	61 (11.5 %)	109 (20.5 %)
Chen LY et al. ⁽¹⁸⁾	Average: 61	278/224	-	-	105 (20.9 %)
Wang Y et al. ⁽¹⁹⁾	Average: 51.2	82/74	-	9 (5.8 %)	4 (2.6 %)
Du RH et al. ⁽²⁰⁾	Average: 70.7	74/35	Chronic liver failure: 2 (1.8 %)	51** (46.8 %)	109 (100 %)
Zhang G et al. ⁽²¹⁾	Average: 49	53/42	-	32 (33.7 %)	-
Chen J et al. ⁽²²⁾	Average: 51	126/123	Chronic hepatitis B: 2 (0.8 %)	22 (8.8 %)	2 (0.8 %)
Zhou F et al. ⁽²³⁾	Average: 56 (between 18 and 87)	119/72	-	50 (26 %)	54 (28.7 %)
Luo S et al. ⁽²⁴⁾	Average: 53.8	102/81	-	-	7 (3.8 %)
Pan L et al. ⁽²⁵⁾	Average: 52.9	107/97	-	16 (7.8 %)	37 (17.7 %)
Teich VD et al. ⁽²⁶⁾	Average: 39.9	290/220	Hepatitis B. C. HIV or other immunodeficiency: 2 (0.4 %)	17 (3.4 %)	1 (1.38 %)
Lei F et al. ⁽²⁷⁾	Average: 56	2724/3047	Chronic liver disease: 81 (1.4 %)	-	-
Chen N et al. ⁽²⁸⁾	Average: 55.5	67/32	-	-	11 (11.1 %)
Yu Y et al. ⁽²⁹⁾	Average: 64 (between 57 and 70)	139/87	Chronic hepatopathy: 3 (1.3 %)	226 (100 %)	9 (4 %)***
Jiang S et al. ⁽³⁰⁾	Average: 51.2	70/61	-	-	-
Hu W et al. ⁽³¹⁾	Average: 44.1	6/10	Steatosis: 3 (18.8 %) Dysfunction: 1 (6.3 %)	0	0
Zhang S et al. ⁽³²⁾	Average: 62	447/381	Chronic liver disease: 23 (3.02 %)	100 (12.08 %)	146 (17.63 %)
Zhang B et al. ⁽³³⁾	Average: 72.5	54/28	Liver disease: 2 (2.4 %)	14 (17.1 %)	82 (100 %)
Shi M et al. ⁽³⁴⁾	Average: 59.38	104/57	-	161 (100 %)	50 (31.06 %)
Ramachandran P et al. ⁽³⁵⁾	Average: between 59.5 and 63	55/90	-	-	56 (38.62 %)
Schattenberg JM et al. ⁽³⁶⁾	Average: 68 (23 and 86)	30/14	Pre-existing liver disease: 10 (23 %)	13 (29.5 %)	2 (4.5 %)
Falasca L et al. ⁽³⁷⁾	Average: 27 and 92	15/7	-	-	22 (100 %)
Richardson S et al. ⁽³⁸⁾	Average: 63	3437/2263	Cirrhosis: 19 (0.4 %) Hepatitis B: 8 (0.1 %) Hepatitis C: 3 (0.1 %)	373 (14.2 %) de 2634 pacientes	553 (21 %) de 2634 pacientes
Davies P et al. ⁽³⁹⁾	Average: 11	52/26	-	78 (100 %)	2 (3 %)
Fan Z et al. ⁽⁴⁰⁾	Average: 50	73/75	-	-	1
Xie H et al. ⁽⁴¹⁾	Average: 60	44/35	-	-	-
Cai Q et al. ⁽⁴²⁾	Average: 47.5	145/153	Alcoholic fatty liver: 5 (1.7 %) Non-alcoholic fatty liver: 9 (3 %) Chronic hepatitis B: 14 (4.7 %)	30 (10.1 %)	3 (1 %)

Data is only from the sample that progressed to death. **All patients needed ICU admission, but there was availability only for 51 patients. ***At the end of the study, there were still 204 patients admitted to the ICU. F: Female; M: Male; HIV: Human Immunodeficiency Virus. Source: Research data, 2020.

Table 5. Findings suggestive of liver injury in the studies included in the review considering increased enzyme activity (AST and ALT), proteins, albumin and bilirubin

Article	AST	ALT	Other
Bahl A et al. ⁽¹³⁾	Elevated in 711 cases	Elevated in 434 cases	-
Zhou J et al. ⁽¹⁴⁾	Elevated in 31 cases	Elevated in 20 cases	-
Jin A et al. ⁽¹⁵⁾	-	-	Different degrees of abnormal liver function in 19 (42%)
Asghar MS et al. ⁽¹⁶⁾	Elevated in 32 cases	Elevated in 22 cases	Increased total bilirubin in 10 cases Increase in GGT in 40/77
Monterde VB et al. ⁽¹⁷⁾	Abnormal* in 221 cases	Elevated in 141 cases	Abnormal liver test in 319 (64.3%) Abnormal GGT in 256 cases
Chen LY et al. ⁽¹⁸⁾	Elevated	-	-
Wang Y et al. ⁽¹⁹⁾	Elevated	-	-
Du RH et al. ⁽²⁰⁾	Elevated in 50 cases	Elevated in 18 cases	-
Zhang G et al. ⁽²¹⁾	Elevated in 11 cases	Elevated	Decrease in total protein in 65 cases
Chen J et al. ⁽²²⁾	Elevated	Elevated	Albumin reduction
Zhou F et al. ⁽²³⁾	-	Increased in 59/189	-
Luo S et al. ⁽²⁴⁾	Slight increase, average: 65.8 ± 12.7 U/L	Slight increase, average: 66.4 ± 13.2 U/L	-
Pan L et al. ⁽²⁵⁾	Elevated in 22 cases	Elevated in 27 cases	-
Teich VD et al. ⁽²⁶⁾	Elevated in 15/70	Elevated in 19/75	Increased total bilirubin in 3 cases
Lei F et al. ⁽²⁷⁾	Elevated	Increased	-
Chen N et al. ⁽²⁸⁾	Elevated in 35 cases	Elevated in 28 cases	Decreased albumin in 97 cases and increased total bilirubin in 18 cases
Yu Y et al. ⁽²⁹⁾	Elevated in 46 cases	Elevated in 85 cases	Decreased albumin in 145 cases and increased total bilirubin in 42 cases
Jiang S et al. ⁽³⁰⁾	Abnormal in 41 cases	Abnormal in 45 cases	Risk factor: treating with several drugs concomitantly
Hu W et al. ⁽³¹⁾	Elevated in 5 cases	Elevated in 5 cases	Decreased albumin in 13 cases and increased total bilirubin in 3 cases
Zhang S et al. ⁽³²⁾	-	Elevated	Increased total bilirubin
Zhang B et al. ⁽³³⁾	Elevated in 44 cases	Abnormal in 42 cases	Decreased albumin in 56 cases and increased total bilirubin in 22 cases
Shi M et al. ⁽³⁴⁾	Elevated in 82 cases	Anormal en 42 casos	Abnormal albumin in 141 cases
Ramachandran P et al. ⁽³⁵⁾	-	-	Increased aminotransferases in 20 cases
Schattenberg JM et al. ⁽³⁶⁾	Elevated in 26 cases	Elevated in 6 cases	Increased GGT in 7 cases
Falasca L et al. ⁽³⁷⁾	-	-	Histopathological changes
Richardson S et al. ⁽³⁸⁾	Elevated in 3263 cases	Elevated in 2176 cases	-
Davies P et al. ⁽³⁹⁾	No changes	No changes	-
Fan Z et al. ⁽⁴⁰⁾	Elevated in 32 cases	Elevated in 27 cases	Increased GGT in 26 cases and bilirubin in 9 cases
Xie H et al. ⁽⁴¹⁾	Elevated in 28 cases	Elevated in 25 cases	Increased total bilirubin in 4 cases
Cai Q et al. ⁽⁴²⁾	Elevated	Elevated	Increased GGT

The values regarding the total sample size, cited in each study presenting hepatic alterations, are described in **Table 1**. *Abnormal: alteration of reference values. Source: Research data, 2020.

with worsening in the clinical course of SARS-CoV-2 infection; this progression was also mentioned in the article by Xie H et al. ⁽³⁶⁾. The condition worsening of these individuals was demonstrated by a greater drop in oxygen saturation, an increase in leukocyte and neutrophil counts, higher levels of CRP, D-dimer, lactate dehydrogenase (LDH) and others. Furthermore, 28.9 % of individuals with altered liver function died; whereas for those with preserved liver function, such rate was of 9 %⁽¹⁷⁾. This study also classified the liver injury severity as normal liver function grade 0 (201 patients); grade 1 (138 patients) hepatocellular or biliary type; and hepatocellular type grade 2 (163 patients) along with biliary type⁽¹⁷⁾.

When analyzing the possibility of in-hospital death, Zhou F et al. ⁽⁴¹⁾ mentioned that elevated ALT was one of the factors increasing this risk, a condition also recorded in other studies^(14,26). Lei F et al. ⁽²⁶⁾ considered that the risk of all-cause mortality increased significantly 4.81 times when AST was altered. Chen J et al. ⁽¹⁶⁾ noted that low albumin levels are among the factors associated with the development of respiratory distress syndrome.

The authors identified histopathological changes in the liver of patients who died from COVID-19, such as inflammatory infiltrate, congestion, and steatosis⁽²¹⁾.

DISCUSSION

In this systematic review, there was a higher prevalence of men. As for COVID-19 laboratory alterations, sex differences are accentuated from the age of 13, with changes in liver function markers common in different age groups, whereas elevation of inflammation biomarkers stand out in older men⁽⁴³⁾.

In the scenario of hepatobiliary biochemical changes, hyperbilirubinemia and elevation of aminotransferases, especially AST, were observed, as well as elevation of GGT, which shows direct or indirect liver damage due to COVID-19⁽⁴⁴⁾. Among the mechanisms that may justify changes in liver function due to SARS-CoV-2 infection is that the exacerbated release of cytokines and the consequent Acute Respiratory Distress Syndrome (ARDS) promote hypoxia and oxidative stress, which can cause liver damage^(45,46). Furthermore, the ACE-II receptor, used by SARS-CoV-2 to enter the cell, is present in the epithelial cells of hepatocytes and the bile duct, which may set up another mechanism that justifies the elevation of observed hepatic enzymes and bilirubin^(4,44).

Regarding the association between changes in hepatocellular markers and the severity of COVID-19 patients, Shi et al. ⁽⁴⁷⁾ described AST at normal levels in asymptomatic patients with SARS-CoV-2 infection; whereas, for symptomatic patients, this marker was elevated, suggesting that changes in liver function reflect a worse prognosis of

COVID-19. Among other factors reported as markers of SARS-CoV-2 infection severity, the reduction in albumin levels, observed in the studies analyzed, stands out, and its relationship with the acute inflammatory phase is worth mentioning^(4,44).

The hepatic impact of COVID-19 on the patient can be measured with a histopathological analysis of the liver, which initially revealed microvascular steatosis and moderate lobular and portal activity^(10,48). In critically ill patients, *postmortem* biopsy shows portal fibrosis, lobular inflammation, and significant vascular thrombosis⁽⁴⁹⁾. Other findings of the necropsy are hepatomegaly, leukocyte infiltration in zone 1, focal necrosis in zone 2 and congestion with mild thrombosis in zone 3⁽⁵⁰⁾.

In the case of chronic liver disease prior to COVID-19, as observed in some of the analyzed studies, these patients present an activation of the alternative pathway of the renin-angiotensin system that promotes a reduction in plasma levels of angiotensin II and also an elevation of ACE-II^(51,52). However, in the literature it is described that, with the entry of SARS-CoV-2 into the cell, there is a decrease in ACE-II and, consequently, an increase in plasma levels of angiotensin II, and the increase in this hormone is related to the viral load and systemic complications of COVID-19^(53,54). Kulkarni et al. hypothesized that patients with chronic liver disease would experience a SARS-CoV-2 infection with fewer complications⁽⁴⁴⁾; however, more studies on the subject are needed to make such a claim.

Due to the absence, so far, of a defined treatment for infection by the novel coronavirus, since it is still necessary to demonstrate the effectiveness of what has already been proposed, the therapeutic approach to this disease involves the administration of drugs that favor the hepatotoxic potential, such as oseltamivir, hydroxychloroquine, paracetamol and acetaminophen^(44,55). Therefore, the importance of studies on the relationship between the liver and COVID-19 is evident, so that health professionals, having this knowledge, can reduce the risk in their patients and thus avoid death due to liver damage from COVID-19, as stated by Zhang et al. ⁽⁵⁶⁾ in their study.

Some factors may be considered limitations in this review study. There were studies published before the clinical outcome of all patients, as in Yu Y et al. ⁽³⁷⁾; consequently, it was not possible to fully assess the prognosis. Du RH et al. ⁽²⁰⁾ mentioned the unavailability of ICU beds for patients who needed it due to patient overload, which can directly interfere with the clinical outcome, given that the deficit in medical care is one of the interference factors.

In addition, several studies did not mention the sample size and described the findings subjectively, such as in the research of Ley F et al. ⁽²⁶⁾ and Zhang S et al. ⁽⁴⁰⁾, who reported that only laboratory changes occurred without iden-

tifying the sample size of the patients studied. Regarding the proposed objectives, it is valid to report that, although there is data in the literature that report the hepatotoxicity of the drugs used to treat COVID-19, most of the articles did not address the condition in their reviews.

CONCLUSION

It is evident that there is a relationship between hepatic involvement from COVID-19 and its mortality, as des-

cribed in the articles. However, there is still a limitation in terms of the number and, more importantly, homogeneity of the studies that performed such assessment. Therefore, it is of the essence to adopt hepatic enzymes as a parameter in the assessment of patients with COVID-19 in future studies, since, as explained in this review, there are reports of the association between their elevation and a higher mortality rate, even if the causing mechanism is not fully clarified, since it is a very recent disease.

REFERENCES

1. World Health Organization. Rolling updates on coronavirus disease (COVID-19) [internet]. Global Pandemic Network; 2020 [9 de septiembre de 2020]. Disponible en: <https://www.globalpandemicnetwork.org/covid-19/international-business-and-global-virtual-teams/rolling-updates-on-coronavirus-disease-covid-19/>
2. Yang P, Wang X. COVID-19: a new challenge for human beings. *Cell Mol Immunol*. 2020 May;17(5):555-557. <https://doi.org/10.1038/s41423-020-0407-x>
3. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*. 2020;323(14):1406-1407. <https://doi.org/10.1001/jama.2020.2565>
4. Padilla Machaca PM, Cárdenas Ramírez BE, Cabrera Cabrejos MC. Impacto del COVID-19 en las enfermedades hepáticas y la salud pública en el Perú. *Rev Gastroenterol Peru*. 2020;40(2):162-72.
5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020;395(10223):514-523. [https://doi.org/10.1016/S0140-6736\(20\)30154-9](https://doi.org/10.1016/S0140-6736(20)30154-9)
6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. <https://doi.org/10.1056/NEJMoa2002032>
7. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020 Jun 16;75(23):2950-2973. <https://doi.org/10.1016/j.jacc.2020.04.031>
8. Joung JY, Cho JH, Kim YH, Choi SH, Son CG. A literature review for the mechanisms of stress-induced liver injury. *Brain Behav*. 2019;9(3):e01235. <https://doi.org/10.1002/brb3.1235>
9. Li J, Li RJ, Lv GY, Liu HQ. The mechanisms and strategies to protect from hepatic ischemia-reperfusion injury. *Eur Rev Med Pharmacol Sci*. 2015;19(11):2036-47.
10. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;8(4):420-422. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X)
11. Gomes BTL, Souza FAP, Pereira IS, Portela BYM, Santos CRB. Avaliação da função hepática: uma revisão bibliográfica. *Mostra Científica de Biomedicina*. 2019;4(1).
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977;33(1):159-74.
13. Asghar MS, Haider Kazmi SJ, Ahmed Khan N, Akram M, Ahmed Khan S, Rasheed U, Hassan M, Memon GM. Correction: Clinical Profiles, Characteristics, and Outcomes of the First 100 Admitted COVID-19 Patients in Pakistan: A Single-Center Retrospective Study in a Tertiary

- Care Hospital of Karachi. *Cureus*. 2020;12(8):c34. <https://doi.org/10.7759/cureus.c34>
14. Bahl A, Van Baalen MN, Ortiz L, Chen NW, Todd C, Milad M, Yang A, Tang J, Nygren M, Qu L. Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. *Intern Emerg Med*. 2020;15(8):1485-1499. <https://doi.org/10.1007/s11739-020-02509-7>
 15. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy*. 2020;75(7):1742-1752. <https://doi.org/10.1111/all.14309>
 16. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect*. 2020;80(5):e1-e6. <https://doi.org/10.1016/j.jinf.2020.03.004>
 17. Chen LY, Chu HK, Bai T, Tu SJ, Wei Y, Li ZL, Hu LL, Zhu R, Zhang L, Han CQ, Xiao L, He Q, Song J, Liu WH, Zhu QJ, Chen H, Yang L, Hou XH. Liver damage at admission is an independent prognostic factor for COVID-19. *J Dig Dis*. 2020;21(9):512-518. <https://doi.org/10.1111/1751-2980.12925>
 18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
 19. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, Johnson M, Griffiths B, du Pré P, Mohammad Z, Deep A, Playfor S, Singh D, Inwald D, Jardine M, Ross O, Shetty N, Worrall M, Sinha R, Koul A, Whittaker E, Vyas H, Scholefield BR, Ramnarayan P. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health*. 2020;4(9):669-677. [https://doi.org/10.1016/S2352-4642\(20\)30215-7](https://doi.org/10.1016/S2352-4642(20)30215-7)
 20. Du RH, Liu LM, Yin W, Wang W, Guan LL, Yuan ML, Li YL, Hu Y, Li XY, Sun B, Peng P, Shi HZ. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. *Ann Am Thorac Soc*. 2020;17(7):839-846. <https://doi.org/10.1513/AnnalsATS.202003-225OC>
 21. Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastri E, Antinori A, Petrosillo N, Marchioni L, Biava G, D'Offizi G, Palmieri F, Goletti D, Zumla A, Ippolito G, Piacentini M, Del Nonno F. Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. *J Infect Dis*. 2020;222(11):1807-1815. <https://doi.org/10.1093/infdis/jiaa578>
 22. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol*. 2020;18(7):1561-1566. <https://doi.org/10.1016/j.cgh.2020.04.002>
 23. Hu W, Chen X, He B, Yuan S, Zhang X, Wu G, Liu J, Xu L, Cha W, Xu M, Sun X, Shen H. Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study. *Ann Transl Med*. 2020;8(10):642. <https://doi.org/10.21037/atm-20-3422>
 24. Jiang S, Wang R, Li L, Hong D, Ru R, Rao Y, Miao J, Chen N, Wu X, Ye Z, Hu Y, Xie M, Zuo M, Lu X, Qiu Y, Liang T. Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. *Front Med (Lausanne)*. 2020;7:347. <https://doi.org/10.3389/fmed.2020.00347>
 25. Jin A, Yan B, Hua W, Feng D, Xu B, Liang L, Guo C. Clinical characteristics of patients diagnosed with COVID-19 in Beijing. *Biosaf Health*. 2020;2(2):104-111. <https://doi.org/10.1016/j.bsheal.2020.05.003>
 26. Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology*. 2020;72(2):389-398. <https://doi.org/10.1002/hep.31301>
 27. Luo S, Zhang X, Xu H. Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). *Clin Gastroenterol Hepatol*. 2020;18(7):1636-1637. <https://doi.org/10.1016/j.cgh.2020.03.043>
 28. Bernal-Monterde V, Casas-Deza D, Letona-Giménez L, de la Llama-Celis N, Calmarza P, Sierra-Gabarda O, Betoré-Glaria E, Martínez-de Lagos M, Martínez-Barredol L, Espinosa-Pérez M, M Arbones-Mainar J. SARS-CoV-2 Infection Induces a Dual Response in Liver Function Tests: Association with Mortality during Hospitalization. *Biomedicines*. 2020;8(9):328. <https://doi.org/10.3390/biomedicines8090328>
 29. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. *Am J Gastroenterol*. 2020;115(5):766-773. <https://doi.org/10.14309/ajg.0000000000000620>
 30. Ramachandran P, Perisetti A, Gajendran M, Chakraborti A, Narh JT, Goyal H. Increased Serum Aminotransferase Activity and Clinical Outcomes in Coronavirus Disease 2019. *J Clin Exp Hepatol*. 2020;10(6):533-539. <https://doi.org/10.1016/j.jceh.2020.06.009>
 31. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA,

- Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052-2059. <https://doi.org/10.1001/jama.2020.6775>
32. Schattenberg JM, Labenz C, Wörns MA, Menge P, Weinmann A, Galle PR, Sprinzl MF. Patterns of liver injury in COVID-19 - a German case series. *United European Gastroenterol J*. 2020;8(7):814-819. <https://doi.org/10.1177/2050640620931657>
 33. Shi M, Chen L, Yang Y, Zhang J, Xu J, Xu G, Li B, Yin Y. Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: A multicenter descriptive study. *J Clin Lab Anal*. 2020;34(9):e23415. <https://doi.org/10.1002/jcla.23415>
 34. Teich VD, Klajner S, Almeida FAS, Dantas ACB, Laselva CR, Torritesi MG, Canero TR, Berwanger O, Rizzo LV, Reis EP, Cendoroglo Neto M. Epidemiologic and clinical features of patients with COVID-19 in Brazil. *Einstein (Sao Paulo)*. 2020;18:eAO6022. https://doi.org/10.31744/einstein_journal/2020ao6022
 35. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol*. 2020;73(4):807-816. <https://doi.org/10.1016/j.jhep.2020.05.002>
 36. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int*. 2020;40(6):1321-1326. <https://doi.org/10.1111/liv.14449>
 37. Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, Xu J, Wu Y, Huang C, Ouyang Y, Yang L, Fang M, Xiao H, Ma J, Zhu W, Hu S, Hu Q, Ding D, Hu M, Zhu G, Xu W, Guo J, Xu J, Yuan H, Zhang B, Yu Z, Chen D, Yuan S, Shang Y. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. *Crit Care*. 2020;24(1):219. <https://doi.org/10.1186/s13054-020-02939-x>
 38. Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, Song Q, Jia Q, Wang J. Clinical characteristics of 82 cases of death from COVID-19. *PLoS One*. 2020;15(7):e0235458. <https://doi.org/10.1371/journal.pone.0235458>
 39. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respir Res*. 2020;21(1):74. <https://doi.org/10.1186/s12931-020-01338-8>
 40. Zhang S, Guo M, Duan L, Wu F, Hu G, Wang Z, Huang Q, Liao T, Xu J, Ma Y, Lv Z, Xiao W, Zhao Z, Tan X, Meng D, Zhang S, Zhou E, Yin Z, Geng W, Wang X, Zhang J, Chen J, Zhang Y, Jin Y. Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. *Crit Care*. 2020;24(1):438. <https://doi.org/10.1186/s13054-020-03123-x>
 41. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
 42. Zhou J, Sun J, Cao Z, Wang W, Huang K, Zheng F, Xie Y, Jiang D, Zhou Z. Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China. *Medicine (Baltimore)*. 2020;99(34):e21824. <https://doi.org/10.1097/MD.00000000000021824>
 43. Ten-Caten F, Gonzalez-Dias P, Castro Í, Ogava RLT, Giddaluru J, Silva JCS, Martins F, Gonçalves ANA, Costa-Martins AG, Araujo JD, Viegas AC, Cunha FQ, Farsky S, Bozza FA, Levin AS, Pannaraj PS, de Silva TI, Minoprio P, Pinheiro da Silva F, Andrade BB, Nakaya HI. In-depth analysis of laboratory parameters reveals the interplay between sex, age, and systemic inflammation in individuals with COVID-19. *Int J Infect Dis*. 2021;105:579-587. <https://doi.org/10.1016/j.ijid.2021.03.016>
 44. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther*. 2020;52(4):584-599. <https://doi.org/10.1111/apt.15916>
 45. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-1034. [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)
 46. Hu LL, Wang WJ, Zhu QJ, Yang L. [Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy]. *Zhonghua Gan Zang Bing Za Zhi*. 2020;28(2):97-99. <https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.001>
 47. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020;20(4):425-434. [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4)
 48. Qi X, Liu C, Jiang Z, Gu Y, Zhang G, Shao C, Yue H, Chen Z, Ma B, Liu D, Zhang L, Wang J, Xu D, Lei J, Li X, Huang H, Wang Y, Liu H, Yang J, Pan H, Liu W, Wang W, Li F, Zou S, Zhang H, Dong J. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. *J Hepatol*. 2020;73(2):455-458. <https://doi.org/10.1016/j.jhep.2020.04.010>
 49. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*. 2020;382(17):1653-1659. <https://doi.org/10.1056/NEJMs2005760>

50. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci.* 2020;63(3):364-374.
<https://doi.org/10.1007/s11427-020-1643-8>
51. Sonzogni A, Prevalenti G, Seghezzi M, Alessio MG, Gianatti A, Licini L, Zerbi P, Carsana L, Rossi R, Lauri E, Pellegrinelli A, Nebuloni M. Liver and COVID 19 infection: a very preliminar lesson learnt from histological post-mortem findings in 48 patients. *Preprints.* 2020; 2020040438.
<https://doi.org/10.20944/preprints202004.0438.v1>
52. Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, Fei G, Ren L, Zhou YW, Liu L. Gross examination report of a COVID-19 death autopsy. *Fa Yi Xue Za Zhi.* 2020;36(1):21-23.
<https://doi.org/10.12116/j.issn.1004-5619.2020.01.005>
53. Casey S, Schierwagen R, Mak KY, Klein S, Uschner F, Jansen C, Praktijnjo M, Meyer C, Thomas D, Herath C, Jones R, Trebicka J, Angus P. Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation. *J Clin Med.* 2019;8(4):419.
<https://doi.org/10.3390/jcm8040419>
54. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. *Gut.* 2005;54(12):1790-6.
<https://doi.org/10.1136/gut.2004.062398>
55. Hodgman MJ, Garrard AR. A review of acetaminophen poisoning. *Crit Care Clin.* 2012;28(4):499-516.
<https://doi.org/10.1016/j.ccc.2012.07.006>
56. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol.* 2020;5(5):428-430.
[https://doi.org/10.1016/S2468-1253\(20\)30057-1](https://doi.org/10.1016/S2468-1253(20)30057-1)